The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 504 participants.

Also called NCT02516826

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 504 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02516826
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02516826. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
Condition
Coronary Syndrome
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Olmesartan
Intervention (Drug)
Combination
Intervention (Drug)
Placebo of Rosuvastatin
Intervention (Drug)
Placebo of Olmesartan
Intervention (Drug)
Placebo of Rosuvastatin/Olmesartan(Combination)
Lead sponsor
Samsung Medical Center (class: other)

Record details

Record id
cardio:ct-nct02516826
Content hash
f2c5d4f463188cb773f9798ef2f3eaf8d824b6dba6d365bbf9575893dba49bc1